Clinical Trial Update: CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism [Phase 2]

View source ↗

Summary

Phase 2 trial update for CSI-Glucagon in children to prevent hypoglycemia in congenital hyperinsulinism; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Hyperinsulinism

Drugs mentioned

• CSI-Glucagon

Snippet

Sponsor: Xeris Pharmaceuticals | Conditions: Congenital Hyperinsulinism | Phase 2 | Status: COMPLETED | Results posted: 2019-12-10